Dipartimento di Fisica e Chimica "Emilio Segrè" (DiFC), Università degli Studi di Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy; CIRCMSB - Consorzio Interuniversitario di Ricerca in Chimica dei Metalli nei Sistemi Biologici, Via Celso Ulpiani, 27, 70125 Bari, Italy.
Dipartimento di Biomedicina, Neuroscienze e Diagnostica avanzata (BIND), Università degli Studi di Palermo, Via del Vespro 129, 90127 Palermo, Italy.
J Inorg Biochem. 2020 Apr;205:110999. doi: 10.1016/j.jinorgbio.2020.110999. Epub 2020 Jan 15.
Ferulic acid (FA) is a natural phenolic phytochemical that has low toxicity and exhibits therapeutic effects against various diseases, behaving as an antioxidant. FA also displays modest antitumor properties that have been reported at relatively high concentrations. With the aim of improving the anti-tumor efficacy of FA, we synthesized the novel compound tributyltin(IV) ferulate (TBT-F). The coordination environment at the tin center was investigated spectroscopically. Following synthesis, chemical characterization and computational analysis, we evaluated TBT-F effects in colon cancer cells. The results showed that TBT-F, at nanomolar range concentrations, was capable of reducing the viability of HCT116, HT-29 and Caco-2 colon cancer cells. On the other hand, FA was completely inefficacious at the same treatment conditions. Cell viability reduction induced by TBT-F was associated with G2/M cell cycle arrest, increase in membrane permeabilization and appearance of typical morphological signs. TBT-F-induced cell death seemed not to involve apoptotic or necroptotic markers whereas autophagic vacuoles appearance and increase in LC3-II and p62 autophagic proteins were observed after treatment with the compound. The autophagy inhibitor bafylomicin A1 markedly prevented the effect of TBT-F on colon cancer cells, thus indicating that autophagy is triggered as a cell death process. Taken together, our results strongly suggest that the novel ferulic derivative TBT-F is a promising therapeutic agent for colon cancer since it is capable of triggering autophagic (type-II) cell death that may be important in case of resistance to classic apoptosis.
阿魏酸(FA)是一种天然酚类植物化学物质,具有低毒性,并表现出对各种疾病的治疗作用,作为一种抗氧化剂。FA 还表现出适度的抗肿瘤特性,在相对较高的浓度下已有报道。为了提高 FA 的抗肿瘤功效,我们合成了新型化合物三丁基锡(IV)阿魏酸酯(TBT-F)。通过光谱学研究了锡中心的配位环境。在合成、化学表征和计算分析之后,我们评估了 TBT-F 对结肠癌细胞的影响。结果表明,TBT-F 在纳摩尔浓度范围内能够降低 HCT116、HT-29 和 Caco-2 结肠癌细胞的活力。另一方面,FA 在相同的治疗条件下完全无效。TBT-F 诱导的细胞活力降低与 G2/M 细胞周期阻滞、膜通透性增加和典型形态学特征的出现有关。TBT-F 诱导的细胞死亡似乎不涉及凋亡或坏死标记物,而在用该化合物处理后观察到自噬空泡的出现和 LC3-II 和 p62 自噬蛋白的增加。自噬抑制剂巴氟霉素 A1 显著阻止了 TBT-F 对结肠癌细胞的作用,这表明自噬被触发为细胞死亡过程。总之,我们的结果强烈表明,新型阿魏酸衍生物 TBT-F 是一种有前途的结肠癌治疗剂,因为它能够触发自噬(II 型)细胞死亡,这在对经典凋亡产生抗性的情况下可能很重要。